Read by QxMD icon Read


Joseph G Christenbury, Nopasak Phasukkijwatana, Anna Tan, K Bailey Freund, David Sarraf
PURPOSE: To describe two cases of dome-shaped macula (DSM) and serous macular detachment, the diagnosis of which was enhanced with a radial optical coherence tomography (OCT) scanning protocol. METHODS: Retrospective case series of DSM associated with serous macular detachment. Multimodal retinal imaging was performed including spectral domain OCT with a radial scan protocol and en face OCT angiography. Anatomical outcomes before and after therapy are presented...
September 30, 2016: Retinal Cases & Brief Reports
Michael N Cohen, Samuel K Houston, Alexander Juhn, Allen C Ho, Carl D Regillo, James Vander, Allen Chiang
OBJECTIVE: To report short-term visual and anatomic outcomes of patients who were switched to aflibercept for persistent macular edema associated with central retinal vein occlusion (CRVO). METHODS: Retrospective, consecutive, interventional case series of 17 patients with persistent macular edema secondary to CRVO (defined as intraretinal edema and either <50 µm reduction in central foveal thickness [CFT] or worsening or no improvement in visual acuity [VA] compared to baseline) despite anti-VEGF treatment who were switched to aflibercept treatment...
October 2016: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
Konstantinos Balaskas, Michael Karampelas, Mania Horani, Oana Hotu, Pearse Keane, Tariq Aslam
PURPOSE: To assess whether best-corrected visual acuity and pigment epithelial detachment (PED) height, volume, and reflectivity in patients with wet age-related macular degeneration are influenced by baseline anatomical and functional parameters, including quantifiable metrics of PED morphology and choice of treatment. METHODS: One hundred two consecutive, treatment-naive wet age-related macular degeneration patients with PED (>50 μm) treated with aflibercept (52) or ranibizumab (50) were retrospectively included...
October 11, 2016: Retina
Jeremy C K Tan, Melissa X Kuo, Minas T Coroneo
PURPOSE: To report on a case of autoconjunctival graft compromise after pterygium surgery in a patient on long-term anti-vascular endothelial growth factor (anti-VEGF) therapy, due to the deleterious effects of anti-VEGF agents on ocular wound healing. METHODS: A white female in her early eighties presented with large right nasal pterygium, first noted 5 years previously. She also had macular degeneration and had been receiving monthly injections of ranibizumab, which was later switched to aflibercept...
October 5, 2016: Cornea
Maria Eleftheriadou, Clara Vazquez-Alfageme, Cristina Maria Citu, Roxanne Crosby-Nwaobi, Sobha Sivaprasad, Philip Hykin, Robin D Hamilton, Praveen J Patel
PURPOSE: To report 2 year treatment outcomes with intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) in routine clinical practice. DESIGN: Retrospective, non-randomized, interventional case series. METHODS: Retrospective analysis of electronic medical record (EMR) notes (OpenEyes), paper case notes and review of spectral-domain optical coherence tomography (SD-OCT) imaging of patients with consecutively treated eyes with previously untreated nAMD...
October 13, 2016: American Journal of Ophthalmology
Masayuki Ohnaka, Yoshimi Nagai, Kenichiro Sho, Katsuaki Miki, Motoki Kimura, Tomoyuki Chihara, Kanji Takahashi
PURPOSE: To evaluate a modified treat-and-extend (TAE) regimen of intravitreal aflibercept injection (IAI) for treatment-naïve patients with neovascular age-related macular degeneration (AMD). METHODS: Thirty-six eyes (36 patients) treated with the modified TAE regimen were evaluated at 12 months retrospectively. The modified TAE regimen consisted of three steps: 1) an induction phase, during which patients were treated with ≥ 3-monthly IAIs until exudative activity disappeared, 2) an observation phase, during which patients were monitored until exudative activity appeared, and 3) a TAE phase, for which the initial treatment interval was determined based on the disease recurrence interval, followed by treatment intervals changing by 2 weeks...
October 14, 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
Lauren Van Lancker, Robert Petrarca, Kyros Moutsouris, Panos Masaoutis, George Kampougeris
PURPOSE: To report the response of participants switching from ranibizumab to aflibercept treatment for neovascular age-related macular degeneration (nAMD) requiring further anti-vascular endothelial growth factor treatment. METHODS: In this retrospective case review of 68 participants treated in a single hospital, all participants, prior to switching, received ranibizumab injections only. Best-corrected visual acuity (BCVA), clinical examination, and optical coherence tomography (OCT) were performed at each visit...
October 3, 2016: European Journal of Ophthalmology
Kyung-Hoon Shin, Tae Gon Lee, Jae Hui Kim, Jong Woo Kim, Chul Gu Kim, Dong Won Lee, Jung Il Han, Young Ju Lew, Han Joo Cho
PURPOSE: To evaluate the efficacy of intravitreal aflibercept monotherapy in submacular hemorrhage (SMH) secondary to wet age-related macular degeneration (AMD). METHODS: This study included 25 eyes in 25 patients with SMH involving the fovea secondary to wet-AMD. All patients were treated with three consecutive monthly intravitreal aflibercept (2.0 mg/0.05 mL) injections, followed by as-needed reinjection. They were followed for at least 6 months. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), and area of SMH were measured at diagnosis, as well as at 3 and 6 months after treatment initiation...
October 2016: Korean Journal of Ophthalmology: KJO
Shira Toledano, Huayi Lu, Agustina Palacio, Boaz Kigel, Ofra Kessler, Gilad Allon, Yoreh Barak, Gera Neufeld, Shlomit Schaal
Abnormal subretinal choroidal neovascularization (CNV) is a major cause of blindness in exudative age-related macular degeneration (AMD). Current anti-angiogenic treatments by VEGF sequestering agents have been successful, but a significant proportion of patients do not respond well to these treatments, and the response of others diminishes over time, suggesting that additional anti-angiogenic agents that function by separate mechanisms may be of use to such patients. We have previously found that a point mutated form of semaphorin-3E resistant to cleavage by furin like pro-protein convertases (UNCL-Sema3E) displays potent anti-angiogenic properties...
October 7, 2016: Experimental Eye Research
Stacey A Strong, Avinash Gurbaxani, Michel Michaelides
BACKGROUND: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that responded on two separate occasions to intravitreal injections of aflibercept, despite previously demonstrating only minimal response to intravitreal ranibizumab. This unique case would support a trial of intravitreal aflibercept for the treatment of RP-associated cystoid macular oedema. CASE PRESENTATION: A 38-year-old man from Dubai, United Arab Emirates, presented to the UK with a 3-year history of bilateral RP-associated cystoid macular oedema...
May 2016: Case Reports in Ophthalmology
J Feliu, I Díez de Corcuera, J L Manzano, M Valladares-Ayerbes, J Alcaide, T García García, R Vera, J Sastre
PURPOSE: In the VELOUR study, aflibercept + FOLFIRI regimen resulted in improved survival in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of aflibercept outside the clinical trial framework needs to be further assessed in terms of effectiveness and tolerability. METHODS: Early access to aflibercept through a named patient programme (NPP) was provided to mCRC patients receiving FOLFIRI as second-line treatment in Spain...
October 7, 2016: Clinical & Translational Oncology
F Ricci, M Parravano, F Regine, M Sciamanna, M Tedeschi, F Missiroli, M Varano
No abstract text is available yet for this article.
October 7, 2016: Eye
D Călugăru, M Călugăru
No abstract text is available yet for this article.
October 7, 2016: Eye
Lee M Jampol, Adam R Glassman, Neil M Bressler, John A Wells, Allison R Ayala
Importance: Post hoc analyses from the Diabetic Retinopathy Clinical Research Network randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema (DME) might influence interpretation of study results. Objective: To provide additional outcomes comparing 3 anti-vascular endothelial growth factor (VEGF) agents for DME. Design, Setting, and Participants: Post hoc analyses performed from May 3, 2016, to June 21, 2016, of a randomized clinical trial performed from August 22, 2012, to September 23, 2015, of 660 participants comparing 3 anti-VEGF treatments in eyes with center-involved DME causing vision impairment...
October 6, 2016: JAMA Ophthalmology
(no author information available yet)
No abstract text is available yet for this article.
October 5, 2016: Japanese Journal of Ophthalmology
Mark C Gillies, Vuong Nguyen, Vincent Daien, Jennifer J Arnold, Nigel Morlet, Daniel Barthelmes
PURPOSE: To directly compare visual acuity (VA) outcomes with ranibizumab vs. aflibercept for eyes with neovascular age-related macular degeneration (nAMD) treated in routine clinical practice. DESIGN: Database observational study. PARTICIPANTS: Treatment-naïve eyes with nAMD tracked by the Fight Retinal Blindness outcome registry that commenced anti-vascular endothelial growth factor therapy with ranibizumab or aflibercept between December 1, 2013, and January 31, 2015...
October 1, 2016: Ophthalmology
Remya Paulose, Jay Chhablani, Chintan J Dedhia, Michael W Stewart, Ahmad M Mansour
AIM: To report the efficacy of intravitreal ziv-aflibercept injections in eyes with macular edema due to retinal vein occlusions (RVOs). METHODS: Consecutive patients with persistent or recurrent macular edema (central macula thickness >250 μm) due to RVO were enrolled in this prospective study. Study eyes received intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL) at baseline. Patients were reassessed monthly for 4 months and given additional injections pro re nata for worsening best-corrected visual acuity (BCVA), intraretinal edema or subretinal fluid seen on spectral domain optical coherence tomography, or central macular thickness (CMT) measurements >250 μm...
2016: Clinical Ophthalmology
Charles C Wykoff, Ryan T Le, Rahul N Khurana, David M Brown, William C Ou, Rui Wang, W Lloyd Clark, David S Boyer
PURPOSE: To determine whether the efficacy and safety achieved with 2.0mg intravitreal aflibercept injections (IAI) for diabetic macular edema (DME) during the phase III VISTA DME trial were maintained with individualized, as-needed treatment. DESIGN: Phase IV, multicenter, open-label extension study. METHODS: Sixty patients completing VISTA DME elected to enter the ENDURANCE extension study. All patients received IAI in the presence of clinically relevant DME...
October 1, 2016: American Journal of Ophthalmology
Yasuo Yanagi, Aya Fukuda, Victor Barzey, Kenji Adachi
OBJECTIVE: This analysis estimated the cost-effectiveness of intravitreal aflibercept injection(s) (IAI) for wet age-related macular degeneration (wAMD) compared with other treatments in Japan. METHODS: This was a cost-utility analysis based on published data. A state-transition cohort model was constructed with six health states based on best-corrected visual acuity in the better-seeing eye. The cycle time was 4 weeks, and the time horizon was 12 years. The model compared IAI 2mg every 8 weeks (2q8) for 2 years after three initial monthly injections, ranibizumab as needed, ranibizumab 0...
October 5, 2016: Journal of Medical Economics
Nakul Singh, Jonathan S Chang, Aleksandra V Rachitskaya
PURPOSE: To analyze anti-vascular endothelial growth factor (anti-VEGF) agent-associated industry payments to ophthalmologists using the Centers for Medicare and Medicaid Services (CMS) Open Payments and Provider Utilization and Payment data. DESIGN: Retrospective database review using two national databases. METHODS: Payments from 2013 to 2014 were analyzed by anti-VEGF agent, payment category, and dollar amount. Ranibizumab and aflibercept usage was correlated by performing logratio analysis...
September 30, 2016: American Journal of Ophthalmology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"